rs104894009 — GCK Arg191Trp (MODY2)

The Broken Glucose Thermostat — GCK Arg191Trp and MODY2

Buried in every pancreatic beta cell is a molecular glucose meter called glucokinase¹¹ glucokinase
Glucokinase (hexokinase-4) is the first enzyme to phosphorylate glucose after it enters the beta cell, committing glucose to the glycolytic pathway. Its unique kinetic properties — low affinity for glucose, non-cooperative kinetics — make it the ideal "glucose sensor" for insulin secretion. Unlike other hexokinases, glucokinase is not inhibited by its product, so its activity rises proportionally with glucose concentration. When blood glucose climbs above roughly 5 mmol/L, glucokinase activity increases, ATP builds up in the beta cell, the KATP channel closes, and insulin is released. GCK is the insulin secretion trigger — it sets the threshold at which the body decides glucose is high enough to warrant an insulin response.

The Arg191Trp variant (rs104894009, also described as p.Gly299Arg in the canonical transcript NM_000162.5) is one of over 700 known pathogenic GCK variants that cause maturity-onset diabetes of the young type 2 (MODY2²² MODY2
MODY is a group of monogenic diabetes syndromes caused by mutations in single genes involved in beta-cell function; MODY2/GCK-MODY is the most common subtype in many European populations). This variant replaces a conserved glycine at the catalytic core with an arginine, reducing glucokinase's catalytic efficiency and raising the glucose threshold for insulin release by approximately 1–2 mmol/L. The result is a thermostat that is permanently set 1–2 degrees too high.

The Mechanism

The Gly299 residue (using canonical transcript numbering) sits within the catalytic domain of glucokinase, close to the glucose-binding site. Substituting glycine — the smallest amino acid with no side chain — with the bulky, positively charged arginine disrupts the local protein architecture. The variant enzyme has reduced catalytic efficiency (lower V_max/K_m ratio)³³ catalytic efficiency (lower V_max/K_m ratio)
Reduced catalytic efficiency means the enzyme needs higher substrate concentrations to reach half its maximum velocity — directly translating to a higher glucose set-point for insulin secretion. Because one normal and one mutant copy of GCK are expressed in the same beta cell, the cell's effective glucose threshold is intermediate between the normal and mutant enzyme's set-points. In heterozygous carriers, this translates clinically to a stable upward shift in fasting glucose of roughly 1–2 mmol/L — from the normal range of 4.0–5.5 mmol/L to approximately 5.4–8.3 mmol/L.

Unlike type 1 diabetes (immune destruction) or type 2 diabetes (progressive insulin resistance and beta-cell exhaustion), GCK-MODY is a static defect. The thermostat is set higher from conception, stays there for life, and does not worsen over time in the absence of other metabolic disease.

The Evidence

The definitive clinical reference is Chakera et al. 2015⁴⁴ Chakera et al. 2015
Chakera AJ et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care, 2015, published in Diabetes Care. This authoritative review synthesized decades of natural history data: heterozygous GCK-MODY carriers have fasting glucose of 5.4–8.3 mmol/L and HbA1c of 5.8–7.6% (40–60 mmol/mol); even after 50 years of mild hyperglycemia, patients do not develop significant microvascular complications such as diabetic retinopathy or nephropathy. Macrovascular risk appears similar to the general population. The paper explicitly states that glucose-lowering therapy is ineffective and not recommended outside pregnancy.

A 2016 Australian review⁵⁵ 2016 Australian review
Bishay RH, Greenfield JR. A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. Med J Aust, 2016 confirmed that GCK-MODY accounts for 10–60% of MODY diagnoses depending on population, that patients rarely develop complications, and that treatment is usually unnecessary and may be safely stopped once the genetic diagnosis is confirmed. This has major practical implications: an estimated 80% of GCK-MODY individuals in the general population have been misdiagnosed as type 1 or type 2 diabetes and are taking medications that do not alter their course.

A Brazilian family study (Caetano et al. 2012⁶⁶ Caetano et al. 2012
Caetano LA et al. Incidental mild hyperglycemia in children: two MODY 2 families identified in Brazilian subjects. Arq Bras Endocrinol Metabol, 2012) directly characterized the Arg191Trp variant: in a single pedigree, 11 of 18 family members tested heterozygous, all with mild fasting hyperglycemia and negative autoimmune markers — confirming stable autosomal dominant transmission and the benign natural history.

Practical Actions

The primary clinical value of identifying this variant is stopping unnecessary treatment. Metformin and sulfonylureas do not alter the glucokinase set-point and provide no benefit in GCK-MODY; insulin in non-pregnant adults is similarly ineffective. Carriers who have been diagnosed with type 1 or type 2 diabetes should discuss genetic testing with their doctor. The diagnostic criteria that should trigger testing include: fasting hyperglycemia in the range of 5.5–8.0 mmol/L present from childhood, HbA1c stably 5.8–7.6%, negative GAD/islet autoantibodies, thin build, and positive family history in multiple generations.

Pregnancy is the one situation requiring active management. When the fetus does NOT carry the GCK mutation, maternal hyperglycemia stimulates excess fetal insulin production, increasing risk of macrosomia. Insulin therapy is therefore recommended only when fetal abdominal circumference exceeds the 75th percentile on ultrasound — a surrogate marker for an unaffected fetus. If the fetus has also inherited the mutation, its own glucose threshold is elevated and it regulates growth normally; treating the mother in that scenario provides no benefit and may cause harm (Timsit et al. 2022⁷⁷ Timsit et al. 2022
Timsit J et al. Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges. Front Endocrinol, 2022).

Interactions

Compound heterozygous or homozygous GCK mutations (two different or two identical pathogenic variants) produce permanent neonatal diabetes requiring insulin from the first weeks of life — a qualitatively different phenotype from the mild hyperglycemia of heterozygous MODY2 (Oza et al. 2022⁸⁸ Oza et al. 2022
Oza CM et al. Variable presentations of GCK gene mutation in a family. BMJ Case Reports, 2022). Heterozygous GCK-MODY carriers who develop obesity and insulin resistance in midlife may transition to a phenotype that more closely resembles type 2 diabetes, as highlighted by Bishay & Greenfield 2016⁹⁹ Bishay & Greenfield 2016
Bishay RH, Greenfield JR. A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. Med J Aust, 2016; the GCK defect persists but an additional metabolic burden (TCF7L2, KCNJ11, or other diabetes risk alleles) can compound the glycemic phenotype. Clinicians should reassess GCK-MODY patients who develop worsening glycemic control after age 40.